Who are "Liraglutide" and "Mitiglinide"'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liraglutide-and-mitiglinide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

"Liraglutide" and "Mitiglinide" — Competitive Intelligence Brief

"Liraglutide" and "Mitiglinide" ("Liraglutide" and "Mitiglinide") competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist + meglitinide combination. Area: Diabetes.

marketed GLP-1 receptor agonist + meglitinide combination GLP-1 receptor (liraglutide); ATP-sensitive potassium channel (mitiglinide) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

"Liraglutide" and "Mitiglinide" ("Liraglutide" and "Mitiglinide") — Third Affiliated Hospital of Third Military Medical University. This combination uses liraglutide (a GLP-1 receptor agonist) to enhance insulin secretion and improve glycemic control, paired with mitiglinide (a meglitinide) to stimulate rapid insulin release from pancreatic beta cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
"Liraglutide" and "Mitiglinide" TARGET	"Liraglutide" and "Mitiglinide"	Third Affiliated Hospital of Third Military Medical University	marketed	GLP-1 receptor agonist + meglitinide combination	GLP-1 receptor (liraglutide); ATP-sensitive potassium channel (mitiglinide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist + meglitinide combination class)

Third Affiliated Hospital of Third Military Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). "Liraglutide" and "Mitiglinide" — Competitive Intelligence Brief. https://druglandscape.com/ci/liraglutide-and-mitiglinide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab